M P Goldman1, R E Fitzpatrick. 1. Department of Dermatology, University of California School of Medicine, San Diego 92037, USA.
Abstract
BACKGROUND: Erythematous and hypertrophic scars may occur after surgical procedures. This paper describes a novel technique for their resolution. OBJECTIVE: The purpose of this paper is to describe long-term results of treating erythematous, hypertrophic scars with the flashlamp-pumped pulsed dye laser (FLPDL). METHODS: Forty-eight patients who presented with erythematous/hypertrophic scars were treated with the FLPDL with or without intralesional triamcinolone. Patients were evaluated by physicians on a 25% increment of objective improvement. RESULTS: Seventy-three percent of scars appearing on the face for less than 1 year totally resolved in an average of 2.3 treatments. Twenty percent of scars on the face for greater than 1 year had a total resolution in 4.4 treatments with an average improvement of 88%. Scars on nonfacial areas for less than 1 year had a 25% incidence of total resolution over an average of 2.5 treatments with an average improvement of 81%. Scars in nonfacial distributions over 1 year of age had a 12% total resolution with an average 62% improvement over 2.2 treatments. CONCLUSION: The FLPDL is a useful adjuvant in the treatment of erythematous, hypertrophic scars.
BACKGROUND:Erythematous and hypertrophic scars may occur after surgical procedures. This paper describes a novel technique for their resolution. OBJECTIVE: The purpose of this paper is to describe long-term results of treating erythematous, hypertrophic scars with the flashlamp-pumped pulsed dye laser (FLPDL). METHODS: Forty-eight patients who presented with erythematous/hypertrophic scars were treated with the FLPDL with or without intralesional triamcinolone. Patients were evaluated by physicians on a 25% increment of objective improvement. RESULTS: Seventy-three percent of scars appearing on the face for less than 1 year totally resolved in an average of 2.3 treatments. Twenty percent of scars on the face for greater than 1 year had a total resolution in 4.4 treatments with an average improvement of 88%. Scars on nonfacial areas for less than 1 year had a 25% incidence of total resolution over an average of 2.5 treatments with an average improvement of 81%. Scars in nonfacial distributions over 1 year of age had a 12% total resolution with an average 62% improvement over 2.2 treatments. CONCLUSION: The FLPDL is a useful adjuvant in the treatment of erythematous, hypertrophic scars.
Authors: Keyvan Nouri; Maria Patricia Rivas; Mark Stevens; Christopher J Ballard; Lauren Singer; Fangchao Ma; Voraphol Vejjabhinanta; Mohamed L Elsaie; George W Elgart Journal: Lasers Med Sci Date: 2009-07-02 Impact factor: 3.161
Authors: Gabriella Fabbrocini; M C Annunziata; V D'Arco; V De Vita; G Lodi; M C Mauriello; F Pastore; G Monfrecola Journal: Dermatol Res Pract Date: 2010-10-14
Authors: Krisztina Vas; Magdolna Gaál; Erika Varga; Réka Kovács; Balázs Bende; Adám Kocsis; Lajos Kemény Journal: Biomed Res Int Date: 2014-09-09 Impact factor: 3.411
Authors: Mahnaz Ramezanpour; Jason L P Smith; Mian Li Ooi; Michael Gouzos; Alkis J Psaltis; P J Wormald; Sarah Vreugde Journal: Sci Rep Date: 2019-02-20 Impact factor: 4.379